Saturday 17 October 2026
Export MRVI’s income statement to Excel — free account
Maravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024. In the quarter to June 2026, revenue grew 8.53%, EPS grew 70.4%, free cash flow grew 127.6% and total debt fell 45.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.79
0.28
−3.96%
Follow MRVI
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 162.76 | 162.76 | 32.87 | 26.86 | 8.20 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | 9 | 8 | 4 | 3 | 4 | 2 |
P/S ratio |
— | 34.19 | 34.19 | 3.99 | 6.02 | 2.04 | 3.08 | 2.90 | 2.53 |
Altman Z-Score |
— | — | — | 0.88 | 4.01 | 2.67 | 1.63 | 1.17 | 0.44 |
P/FCF ratio |
— | 77.61 | 77.61 | 7.03 | 13.58 | 3.47 | 14.66 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 0.59 | 0.74 | 1.82 | 4.88 | 5.08 | 4.37 | 2.71 | 1.29 |
P/Operating CF |
— | 147.38 | 147.38 | 14.28 | 81.88 | 18.13 | 114.14 | (51.34) | (20.61) |
Beneish M-Score |
— | — | (2.61) | (1.58) | (0.70) | (2.32) | (4.09) | (3.93) | (3.30) |
P/B ratio |
— | 52.41 | 52.41 | 7.33 | 8.82 | 1.99 | 1.13 | 1.30 | 1.26 |
Price to Tangible BV |
— | 52.41 | 52.41 | 0.00 | 17.49 | 4.45 | 3.66 | 3.38 | 5.11 |
EV/Sales |
— | 35.84 | 35.84 | 5.24 | 5.99 | 1.92 | 3.01 | 2.92 | 3.09 |
EV/EBITDA |
— | 67.16 | 67.16 | 10.09 | 8.11 | 2.76 | 43.38 | 0.00 | 0.00 |
EV/Operating CF |
— | 82.02 | 82.02 | 9.78 | 12.99 | 3.16 | 6.89 | 101.30 | (9.97) |
EV/FCF |
— | 81.35 | 81.35 | 9.23 | 13.52 | 3.27 | 14.34 | (34.07) | (8.12) |
Quick Ratio |
— | 1.05 | 1.45 | 2.20 | 7.13 | 7.07 | 7.20 | 6.34 | 5.40 |
Current Ratio |
— | 1.50 | 2.05 | 2.54 | 7.89 | 7.70 | 8.00 | 7.53 | 6.60 |
Net Debt/EBITDA |
— | 7.90 | 7.34 | 2.40 | (0.03) | (0.17) | (0.94) | (0.03) | (0.69) |
Debt/Assets |
0.00% | 62.98% | 67.53% | 46.49% | 27.66% | 23.11% | 37.38% | 32.44% | 41.78% |
Debt/Equity |
— | 2.30 | 2.70 | 3.82 | 0.97 | 0.58 | 0.70 | 0.57 | 0.86 |
Asset Turnover |
— | 0.46 | 0.26 | 0.31 | 0.50 | 0.42 | 0.15 | 0.21 | 0.21 |
Operating CF/Net income |
— | 0.04 | (5.39) | 1.98 | 2.02 | 2.43 | (1.06) | (0.05) | 0.44 |
Capex/Depreciation |
— | (0.15) | (0.66) | 0.33 | (0.39) | (0.42) | (1.27) | (0.50) | (0.21) |
Interest Coverage |
— | 0.60 | 0.80 | 3.90 | 18.33 | 28.13 | (0.69) | (4.94) | (7.98) |
| — | (3.14%) | (3.05%) | 51.37% | 52.00% | 30.36% | (14.04%) | (21.19%) | (27.53%) | |
| — | (1.66%) | (0.80%) | 8.32% | 11.42% | 10.48% | (6.31%) | (11.61%) | (14.70%) | |
ROIC |
— | 2.20% | 2.94% | 14.71% | 66.07% | 44.83% | (2.57%) | (25.31%) | (28.16%) |
Return on Tangible Assets |
— | (7.40%) | (3.57%) | 25.45% | 26.28% | 27.86% | (15.35%) | (26.99%) | (32.46%) |
Average Days of Receivables |
— | 47.13 | 45.98 | 65.55 | 53.67 | 60.69 | 68.98 | 54.25 | 50.11 |
Research and Development Expense of Revenue |
— | 3.63% | 2.53% | 3.27% | 1.90% | 2.08% | 5.98% | 7.42% | 9.37% |
Selling, General and Administrative Expense of Revenue |
— | 33.27% | 33.78% | 33.17% | 12.52% | 14.64% | 52.39% | 62.42% | 78.13% |
Intangible Assets out of Total Assets |
0.00 | 0.82 | 0.73 | 0.32 | 0.14 | 0.22 | 0.37 | 0.35 | 0.36 |
Share Based Compensation of Revenue |
— | 1.71% | 1.17% | 8.67% | 1.31% | 2.11% | 11.97% | 19.07% | 16.25% |
Graham Net Nets |
— | 0.01 | 0.01 | (0.69) | (0.13) | (0.29) | 0.00 | 0.00 | (0.22) |
Graham Number |
— | 0.00 | 0.00 | 8.57 | 12.91 | 16.08 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | 0.61% | 0.61% | 3.04% | 3.72% | 12.20% | (13.35%) | (18.72%) | (27.69%) |
Free Cash Flow Yield |
— | 1.29% | 1.29% | 14.22% | 7.37% | 28.81% | 6.82% | (2.95%) | (15.07%) |
Revenue per Share |
— | 0.49 | 0.56 | 27.45 | 6.96 | 6.71 | 2.19 | 1.88 | 1.29 |
Operating CF per Share |
— | 0.00 | 0.10 | 14.70 | 3.21 | 4.07 | 0.96 | 0.05 | (0.40) |
Capex per Share |
— | (0.01) | (0.07) | 0.88 | (0.12) | (0.13) | (0.50) | (0.22) | (0.09) |
Free Cash Flow per Share |
— | (0.01) | 0.03 | 15.58 | 3.09 | 3.94 | 0.46 | (0.16) | (0.49) |
Cash per Share |
— | 0.09 | 0.10 | 22.82 | 4.80 | 4.81 | 4.36 | 2.34 | 1.50 |
Shareholders Equity per Share |
— | 0.58 | 0.57 | 14.95 | 4.75 | 6.88 | 5.99 | 4.19 | 2.58 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.58 | 0.57 | 14.95 | 4.75 | 6.88 | 5.99 | 4.19 | 2.58 |
Free Cash Flow |
— | (3.80) | 6.97 | 161.28 | 354.27 | 518.89 | 60.67 | (22.49) | (70.72) |
Working Capital |
— | 17.88 | 30.99 | 200.82 | 646.26 | 737.76 | 612.44 | 372.18 | 251.33 |
Capital Expenditures |
— | (3.61) | (17.15) | 9.09 | (14.30) | (17.09) | (65.55) | (29.96) | (13.15) |
Net Current Asset Value |
— | (337.86) | (372.62) | (784.35) | (632.88) | (529.17) | 2.35 | (1.89) | (101.61) |
EV/EBIT |
— | 0.00 | 0.00 | 12.42 | 8.63 | 2.95 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.03 | 0.12 | (0.03) | 0.02 | 0.02 | 0.23 | 0.12 | 0.07 |
Price to Operating Income |
— | 0.00 | 0.00 | 9.46 | 8.67 | 3.14 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.56 | 0.27 | 0.27 | 0.78 | 0.78 | 0.32 | 0.36 | 0.41 |
Cash ROIC |
— | (0.74%) | 1.25% | 16.43% | 21.77% | 25.13% | 3.16% | (1.83%) | (7.76%) |
Accounts Receivable Turnover |
— | 7.08 | 8.41 | 8.23 | 9.48 | 6.68 | 2.87 | 5.57 | 5.80 |
Accounts Payable Turnover |
— | 11.05 | 12.06 | 10.18 | 17.22 | 23.89 | 17.79 | 13.30 | 20.41 |
Inventory Turnover |
— | 4.34 | 4.69 | 3.35 | 3.31 | 3.57 | 3.15 | 2.97 | 3.35 |
Average Days of Payables |
— | 21.65 | 40.83 | 37.44 | 21.17 | 12.94 | 26.33 | 28.93 | 7.00 |
Days of Inventory on Hand |
— | 85.94 | 77.54 | 152.61 | 133.88 | 93.22 | 126.12 | 121.16 | 97.40 |
Average Receivables |
— | 17.50 | 17.01 | 34.52 | 84.27 | 132.16 | 100.71 | 46.56 | 32.01 |
Average Payables |
— | 5.50 | 5.54 | 7.82 | 8.16 | 7.07 | 8.36 | 11.34 | 7.43 |
Average Inventory |
— | 14.00 | 14.26 | 23.75 | 42.43 | 47.35 | 47.27 | 50.74 | 45.29 |
Average Assets |
— | 269.84 | 558.74 | 924.24 | 1,594.48 | 2,100.30 | 1,884.88 | 1,247.85 | 889.41 |
Average Common Equity |
— | 142.50 | 146.32 | 149.69 | 350.05 | 725.30 | 847.56 | 683.55 | 474.96 |
Columns are period end dates